Cingulate(US:CING)2026-03-18 12:10Financial Performance - Cingulate reported a net loss of $6.3 million for Q4 2025, compared to a net loss of $6.2 million in Q4 2024, and a total net loss of $22.4 million for the full year 2025, up from $16.6 million in 2024[12]. - As of December 31, 2025, Cingulate had approximately $11.0 million in cash and cash equivalents, a decrease of $1.3 million from the previous year, with expectations to meet capital needs into late Q4 2026[9]. - Research and development expenses for Q4 2025 were $2.0 million, down from $4.3 million in Q4 2024, while total R&D expenses for the year were $9.8 million, slightly up from $9.4 million in 2024[10]. - General and administrative expenses increased to $3.6 million in Q4 2025 from $1.9 million in Q4 2024, totaling $10.2 million for the year compared to $6.2 million in 2024[11]. Intellectual Property - Cingulate received a U.S. Patent Notice of Allowance for CTx-1301, expected to provide protection through May 2042, strengthening its intellectual property portfolio[3]. - A European patent for CTx-1301 was granted, extending protection through May 2042 and expected to be validated in over 30 European territories[4]. Regulatory Developments - The FDA accepted the New Drug Application (NDA) for CTx-1301 in October 2025, with a target action date of May 31, 2026[7]. Financing and Investment - Cingulate closed a $12 million private investment in public equity (PIPE) financing in February 2026, with insider participation and a 180-day lock-up agreement[8]. Commercial Strategy - The company is advancing its commercial readiness, including scaling manufacturing and preparing distribution capabilities[6]. - Cingulate aims to build long-term value for patients and shareholders through its proprietary Precision Timed Release™ (PTR™) platform technology[2].